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S U M M A R Y
Background: Risk factors and outcome in patients who acquire nosocomial infections due to
carbapenem-resistant Acinetobacter baumannii (CRAB) are rarely investigated.
Methods: A multicenter retrospective study was conducted to analyze the clinical and microbiological
data of patients with nosocomial infections due to A. baumannii in 10 hospitals around Taiwan fromMay
2004 to December 2006. Comparisons were made between patients with infections due to CRAB and
patients with infections due to carbapenem-susceptible A. baumannii (CSAB).
Results: One hundred and twenty-one patients carrying CRAB (infections, n = 91) and 127 patients
carrying CSAB (infections, n = 97) were recruited for analysis. Compared with patients with CSAB
infections, patients with CRAB infections had a longer duration of hospital stay before A. baumanniiwas
isolated (median 48 vs. 21 days, p < 0.001) and were more likely to have had exposure to a carbapenem
(adjusted odds ratio (AOR) 2.57, 95% conﬁdence interval (95% CI) 1.43–5.35; p = 0.02) and an intensive
care unit (ICU) stay (AOR 3.42, 95% CI 1.76–5.26; p = 0.008). Risk factors associated with CRAB
bacteremia included duration of hospital stay before onset of bacteremia (AOR 1.009 per 1-day longer,
95% CI 1.03–1.24; p = 0.049), prior colonization with A. baumannii (AOR 3.27, 95% CI 1.99–5.93;
p = 0.002), and hospitalization in the ICU (AOR 6.12, 95% CI 1.58–13.68; p = 0.009). Patients with CRAB
bacteremia had a higher mortality rate than patients with CSAB bacteremia (46.0% vs. 28.3%, p = 0.04).
Multivariate analysis showed that carbapenem resistance (AOR 5.31, 95% CI 1.88–13.25; p = 0.002),
central venous catheterization (AOR 3.27, 95% CI 1.55–10.56; p = 0.009), and ICU stay (AOR 2.56, 95% CI
1.15–8.85; p = 0.04) were independent variables associated with mortality in patients with A. baumannii
bacteremia.
Conclusions: Patients with CRAB infections have a higher mortality rate than those with CSAB infections.
Longer hospital stay, colonization with A. baumannii, and admission to the ICU were associated with the
development of CRAB bacteremia.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acinetobacter baumannii has become one of the most
important pathogens causing nosocomial infections.1–4 Coloni-
zation with and infections caused by A. baumannii are challenges
to infection control and treatment, because it can survive for longses. Published by Elsevier Ltd. All rights reserved.
W.-H. Sheng et al. / International Journal of Infectious Diseases 14 (2010) e764–e769 e765periods in wet environments and it is inherently resistant to
multiple antibiotics.5,6 Carbapenems are the antibiotics of choice
for the treatment of serious infections due to A. baumannii.3,4
Unfortunately, the prevalence of A. baumannii isolates that are
resistant to carbapenems (carbapenem-resistant A. baumannii
(CRAB)) is increasing.2–5 For example, the prevalence of A.
baumannii isolates that were susceptible to imipenem decreased
from 98% in 1995 to 76% in 2006 at a university hospital in
Taiwan.7 Although a variety of risk factors for the acquisition of
CRAB have been reported, most of these studies enrolled patients
hospitalized in intensive care units (ICU)8–12 or patients who
were involved in outbreaks of nosocomial infections.6,8,9,13 In
addition, the link between the acquisition of CRAB and clinical
outcome is less well established.
In this study, we aimed to compare the demographics and
clinical characteristics, antibiotic exposure, and outcome between
patients with infections due to CRAB and patients with infections
due to carbapenem-susceptible A. baumannii (CSAB) who were
hospitalized in 10 hospitals around Taiwan.
2. Methods
2.1. Study population
The Taiwan Surveillance of Antimicrobial Resistance (TSAR)
program was initiated by the National Health Research Institutes
(NHRI), Taiwan, in 1998 to monitor the trends and spectrum of
antimicrobial resistance in Taiwan. In the program, clinical isolates
were collected from inpatients and outpatients of several medical
centers and regional hospitals around Taiwan over a three-month
period, every two years. In the present study, clinical and
microbiological data of patients infected with A. baumannii at
the National Taiwan University Hospital (NTUH) were collected
using a standardized case record form fromMay 2004 toNovember
2006, while those of patients infected with A. baumannii from nine
other hospitals were collected in 2006. Of the 10 hospitals, seven
are medical centers that provide both primary and tertiary care,
including cancer therapy and organ transplantation, and three are
community hospitals that provide primary care. During the study
period, only the ﬁrst episode in which A. baumanniiwas isolated in
each patientwas included for clinical andmicrobiological analyses,
and patients who were identiﬁed in any outbreak of A. baumannii
infection were excluded.
2.2. Case deﬁnitions and collection of data
Patients with colonization or infection with A. baumannii and
the type of infection were assessed following the criteria proposed
by the Centers for Disease Control and Prevention (CDC).14 In brief,
infection with A. baumanniiwas deﬁned in the presence of clinical
symptoms or signs of infection and A. baumannii isolated from
clinical specimens obtained from sterile sites (such as blood,
ascites, pleural effusion, cerebrospinal ﬂuid, joint effusion) and
pus, tissue, or ﬂuid obtained during surgery or needle aspiration.
Patients with surgical wound infections were enrolled if they had
fever (>38 8C) and localized pain or tenderness, with A. baumannii
isolated from cultures of discharge specimens obtained from the
incision wound or closed drainage. A case of primary bloodstream
infection due to A. baumanniiwas deﬁned in the presence of fever,
chills, or hypotension with A. baumannii being isolated from blood
cultures without concurrent isolation of the pathogen from other
sites. A case of lower respiratory tract infection was deﬁned in the
presence of new onset of purulent sputum, change in character-
istics of sputum, presence of new or progressive inﬁltrates,
consolidation, cavitation, or pleural effusion on chest radiography,
with A. baumannii being isolated from blood cultures or cultures oftranstracheal aspirate, bronchial brushing, or lung biopsy. A case of
urinary tract infection was deﬁned in the presence of urinary
urgency, frequency, dysuria, suprapubic tenderness, or pyuriawith
A. baumannii the only isolate cultured from a urine specimen at a
colony count of >105 colonies/ml. A case of colonization with A.
baumannii was deﬁned when there was isolation of A. baumannii
from the skin, mucous membranes, open wounds, or excretions or
secretions, in the absence of relevant signs or symptoms in the
patients.
At each hospital, microbiological data of the patients with
infections due to A. baumannii (infection group) were reviewed for
at least the year before the episode of A. baumannii infection in
order to determine if prior colonization with A. baumannii existed.
Clinical data of the patients, including age, sex, underlying
systemic illnesses, dates of hospital and ICU admissions, previous
colonization with A. baumannii, sites of positive cultures, invasive
procedures and antibiotic use before A. baumannii were isolated,
physical ﬁndings, results of blood biochemical tests, and duration
of hospitalization, were recorded. Prior exposure to antibiotics was
deﬁned as receipt of antimicrobials for at least 72 h during the 30-
day period prior to the isolation of A. baumannii. CRAB was deﬁned
if an A. baumannii isolate was resistant to both imipenem and
meropenem, while CSABwas deﬁned if an A. baumannii isolate was
susceptible to both imipenem and meropenem. Consensus meet-
ings involving all investigators and research nurses were held
before and during data collection. All data were recorded by awell-
trained research nurse and reviewed by an infectious disease
specialist at each hospital. Mortality was deﬁned as deaths
documented to have occurred within 30 days after colonization
or infection with A. baumannii; death associated with A. baumannii
infection in the same hospital stay was counted as attributable
mortality.
2.3. Microbiology
A. baumanniiwere identiﬁed using conventionalmethods15 and
the VITEK AutoMicrobic System (bioMerieux Vitek, Hazelwood,
MO, USA) or API ID 32 GN Kit System (bioMerieux, Marcy-l’Etoile,
France). The minimum inhibitory concentrations (MICs) of
imipenem and meropenem against A. baumanniiwere determined
by agar dilutionmethod at NTUH and by brothmicrodilution using
custom-designed 96-well panels (Sensititre, Trek Diagnostics, East
Grinstead, UK) at NHRI according to the guidelines of the Clinical
and Laboratory Standards Institute (CLSI).16 The isolates of A.
baumannii with a MIC of 8 mg/ml for both imipenem and
meropenemwere recorded as CRAB and thosewithMICs<8 mg/ml
for both imipenem and meropenem were CSAB. To prevent
confusion, A. baumannii isolates that were susceptible to imipenem
but resistant to meropenem, or vice versa, were excluded from the
analysis.
2.4. Statistical analyses
Statistical analyses were performed using SAS statistical
software v. 8.2 (SAS Institute Inc., Cary, NC, USA). Continuous
variables were compared using the Mann–Whitney U-test or
Student’s t-test, and categorical variableswere compared using the
Chi-square test or Fisher’s exact test. Variables with a p-value<0.2
in the univariate analysis were entered into amultivariate analysis
using the multiple logistic regression method to determine the
independent variables that were associated with carbapenem
resistance and mortality. All tests were two-tailed and a p-value
<0.05 was considered signiﬁcant. Adjusted odds ratios (AOR) and
95% conﬁdence intervals (95% CI) were computed for variables
independently associated with carbapenem resistance and mor-
tality.
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During the study period, 248 patients with A. baumannii
isolated from clinical specimens (121 with CRAB and 127 with
CSAB) were identiﬁed fromNTUH (n = 120; 58 CRAB and 62 CSAB)
and nine other hospitals in the TSAR program (n = 128; 63 CRAB
and 65 CSAB). Themedian age was 63 years (range<1 to 97 years)
and 155 (62.5%) patients were male. All of the patients had
underlying systemic illnesses and most of them (92.3%) had
previously received antimicrobial treatment. Half of the patients
(n = 125, 50.4%) had been hospitalized in the ICU before A.
baumannii was isolated. One hundred and eighty-eight patients
were diagnosed as having A. baumannii infections according to
pre-deﬁned criteria, including 91 patients with CRAB infections
(cases) and 97 patients with CSAB infections (controls). The
infection sites included blood (n = 123, 65.4%), respiratory tract
(n = 24, 12.8%), surgical sites (n = 16, 8.5%), urinary tract (n = 15,
8.0%), and others (n = 10, 5.3%).
Clinical characteristics of the patients colonized and infected
with CRAB and CSAB are shown in Table 1. There were no
statistically signiﬁcant differences with respect to age, sex,
underlying diseases, colonization or infection of A. baumannii,
and isolation sites between these two groups. Compared to
patients with CSAB, patients infected with CRAB had higher
proportions of prior hospitalization (89.0% vs. 53.6%, p < 0.001),
prior colonization with A. baumannii (51.6% vs. 9.3%, p < 0.001),
and prior antibiotic use (87.9% vs. 73.2%, p = 0.01), a longer hospital
stay before A. baumanniiwas isolated (median 48 days vs. 21 days,
p < 0.001), and a higher proportion of patients who had ever
stayed in the ICU (69.2% vs. 24.7%, p < 0.001).
Prior antibiotic use, clinical presentations, invasive procedures,
and outcomes are shown in Table 2. Compared with patients
infected with CSAB, more patients with CRAB infections had prior
use of carbapenems and penicillins; presentations of tachycardia,
leukocytosis or leukopenia, and tachypnea; and receipt of invasive
procedures, such as central venous catheterization, urinaryTable 1
Comparisons of demographic and clinical characteristics between patients colonized an
carbapenem-susceptible Acinetobacter baumannii (CSAB)
Characteristics Colonization
CRAB (n=30)
Age, median (range), years 61 (5–93)
Male sex (%) 21 (70)
Underlying systemic illnesses, n (%)
Diabetes mellitus 10 (33.3)
Renal disease 8 (26.7)
Cardiac disease 14 (46.7)
Gastrointestinal disease 2 (6.7)
Malignancy 11 (36.7)
Respiratory disease 13 (43.3)
Cerebrovascular accident 4 (13.3)
Hepatobiliary disease 1 (3.3)
Other 12 (40)
Prior colonization of A. baumannii among infected patients, n (%) –
Related to hospitalization, n (%)
Ever hospitalized within one year 18 (60)
Ever used antibiotics within 28 days 20 (66.7)
Time at risk,a median (range), days 40 (6–214)
Ever stayed in ICU 22 (73.3)




Surgical wound swab/pus 3 (10)
Other 7 (23.3)
ICU, intensive care unit.
a Time at risk was deﬁned as length of hospital stay prior to isolation of A. baumanncatheterization, mechanical ventilation, and total parenteral
nutrition. Patients infected with CRAB had a much longer hospital
stay after the acquisition of CRAB (median 37 days vs. 23 days,
p = 0.009) and had a higher rate of mortality than patients infected
with CSAB (33.0% vs. 17.5%, p = 0.01).
By multivariate analysis, longer duration of hospital stay
(p = 0.01), prior carbapenem use (AOR 2.57, 95% CI 1.43–5.35;
p = 0.02), and a prior hospital stay in the ICU (AOR 3.42, 95% CI
1.76–5.26; p = 0.008) were independent risk factors associated
with CRAB infection.
The data of 123 patients with A. baumannii bacteremia were
analyzed (Table 3). Similarly, compared with patients with CSAB
bacteremia, patients with CRAB bacteremia were more likely to
have had prior antibiotic use, hospitalization in the ICU, prior
colonization with A. baumannii, a longer hospital stay before the
onset of A. baumannii bacteremia, and prior invasive procedures.
Patients with CRAB bacteremia had a longer hospital stay after the
onset of bacteremia and a higher mortality rate than patients with
CSAB bacteremia.
Multivariate analysis showed that longer duration of hospital
stay (AOR 1.009 per 1-day longer, 95% CI 1.03–1.24; p = 0.049),
prior colonization with A. baumannii (AOR 3.27, 95% CI 1.99–
5.93; p = 0.002), and ICU stay (AOR 6.12, 95% CI 1.58–13.68;
p = 0.009) were independently associated with CRAB bacter-
emia. Carbapenem resistance (AOR 5.31, 95% CI 1.88–13.25;
p = 0.002), central venous catheterization (AOR 3.27, 95% CI
1.55–10.56; p = 0.009), and ICU stay (AOR 2.56, 95% CI 1.15–
8.85; p = 0.04) were independent variables that were associated
with attributable mortality in patients with A. baumannii
bacteremia.
4. Discussion
Over recent decades, A. baumannii has rapidly emerged as an
important nosocomial pathogen, and outbreaks due to carbape-
nem-resistant A. baumannii have been increasing, which ared patients infected with carbapenem-resistant Acinetobacter baumannii (CRAB) and
p-Value Infection p-Value
CSAB (n=30) CRAB (n=91) CSAB (n=97)
64 (7–88) 0.54 67 (<1–89) 61 (10–97) 0.26
20 (66.7) 0.79 60 (65.9) 54 (55.7) 0.15
5 (16.7) 0.23 28 (30.8) 29 (29.9) 0.90
7 (23.3) 0.77 22 (24.2) 17 (17.5) 0.26
10 (33.3) 0.29 28 (30.8) 29 (29.9) 0.90
3 (10) 0.99 11 (12.1) 8 (8.2) 0.38
15 (50) 0.30 26 (28.6) 33 (34.0) 0.42
10 (33.3) 0.43 17 (18.7) 11 (11.3) 0.16
7 (23.3) 0.51 16 (17.6) 17 (17.5) 0.99
2 (6.7) 0.99 5 (5.5) 6 (6.2) 0.99
10 (33.3) 0.59 21 (23.1) 13 (13.4) 0.09
– – 47 (51.6) 9 (9.3) <0.001
12 (40) 0.06 81 (89.0) 52 (53.6) <0.001
14 (46.7) 0.11 80 (87.9) 71 (73.2) 0.01
24 (5–179) 0.009 48 (3–264) 21 (6–367) <0.001
16 (53.3) 0.11 63 (69.2) 24 (24.7) <0.001
– 63 (69.2) 60 (61.9) 0.29
15 (50) 0.60 14 (15.4) 10 (10.3) 0.30
5 (16.7) 0.70 7 (7.7) 8 (8.2) 0.89
4 (13.3) 0.99 5 (5.5) 11 (11.3) 0.15
6 (20) 0.75 2 (2.2) 8 (8.2) 0.12
ii from clinical specimens.
Table 2
Comparisons of prior antibiotic usage, clinical presentation, invasive procedures, and ﬁnal outcome between patients colonized and patients infected with carbapenem-
resistant Acinetobacter baumannii (CRAB) and carbapenem-susceptible Acinetobacter baumannii (CSAB)
Characteristics, n (%) Colonization p-Value Infection p-Value
CRAB (n=30) CSAB (n=30) CRAB (n=91) CSAB (n=97)
Prior antibiotics usage (overall) 28 (93.3) 26 (86.7) 0.39 88 (96.7) 87 (89.7) 0.03
Cephalosporin 12 (40) 19 (63.3) 0.07 36 (39.6) 64 (66.0) <0.001
Fluoroquinolone 9 (30) 6 (20) 0.37 25 (27.4) 16 (16.5) 0.07
Carbapenem 19 (63.3) 7 (23.3) 0.002 54 (59.3) 18 (18.6) <0.001
Aminoglycoside 10 (33.3) 10 (33.3) >0.99 28 (30.8) 26 (26.8) 0.55
Penicillin 18 (60) 11 (36.7) 0.07 55 (60.4) 37 (38.1) 0.002
Othera 13 (43.3) 15 (50) 0.60 38 (41.8) 39 (40.2) 0.83
Clinical presentation
Abnormal temperature 20 (66.7) 18 (60) 0.59 61 (67.0) 58 (59.8) 0.31
Tachycardia 21 (70) 16 (53.3) 0.18 65 (71.4) 49 (50.5) 0.003
Hypotension 6 (20) 6 (20) <0.001 13 (14.3) 19 (19.6) 0.33
Leukocytosis/leukopenia 18 (60) 16 (53.3) 0.60 59 (64.8) 48 (49.5) 0.03
Tachypnea 16 (53.3) 12 (40) 0.30 47 (51.6) 33 (34.0) 0.01
Prior invasive procedure
Central venous catheterization 12 (40) 16 (53.3) 0.30 63 (69.2) 39 (40.2) <0.001
Urinary catheterization 18 (60) 13 (43.3) 0.20 56 (61.5) 27 (27.8) <0.001
Mechanical ventilation 12 (40) 14 (46.7) 0.60 48 (52.7) 35 (36.1) 0.02
Hemodialysis 7 (23.3) 4 (13.3) 0.50 15 (16.5) 8 (8.2) 0.09
Total parenteral nutrition 6 (20) 3 (10) 21 (23.1) 11 (11.3) 0.03
Outcome
Length of stay after A. baumannii isolated,
median (range), days
41 (5–282) 29 (2–227) 0.03 37 (1–218) 23 (1–151) 0.009
Mortalityb 4 (13.3) 6 (20) 0.73 30 (33.0) 17 (17.5) 0.01
a Other antibiotics included clindamycin, macrolides, metronidazole, minocycline, teicoplanin, vancomycin, and antifungal agents. Polymyxin and tigecycline were not
available in Taiwan during the study period.
b Mortality was deﬁned as deaths documented within 30 days after colonization with A. baumannii; attributable mortality was deﬁned as deaths associated with A.
baumannii infection in the same hospital stay.
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Acinetobacter species has been estimated to be 6–16% in Western
countries2–4 and 22–32% in Taiwan,17,18 and the trends in
carbapenem resistance in Acinetobacter species are still increasing.
Thus, infection due to CRAB is not only an important issue forTable 3
Comparisons of demographics, clinical characteristics, antibiotic use, clinical presentati
baumannii (CRAB) bacteremia and patients with carbapenem-susceptible Acinetobacter
Factor, n (%)











Ever hospitalized within one year
Ever used antibiotics within 28 days
Time at risk,a median (range), days
ICU stay








Length of stay after onset of A. baumannii bacteremia, median (range), days
Attributable mortalityb
ICU, intensive care unit.
a Time at risk was deﬁned as length of hospital stay prior to isolation of A. baumann
b Attributable mortality was deﬁned as deaths associated with A. baumannii bacterepublic health, but also a challenge for clinicians in the treatment
and control of nosocomial infections.
Multicenter studies on the clinical features and epidemiology of
colonization and infection due to A. baumannii are scarce.19 Risk
factors for nosocomial acquisition of antibiotic-resistant micro-ons, and ﬁnal outcome between patients with carbapenem-resistant Acinetobacter
baumannii (CSAB) bacteremia
CRAB bacteremia CSAB bacteremia p-Value
(n=63) (n=60)
61 (<1–93) 57 (8–92) 0.36
41 (65.1) 32 (53.3) 0.18
26 (41.3) 22 (36.7) 0.60
19 (30.2) 10 (17.0) [16.7] 0.09
19 (30.0) [30.2] 18 (30) 0.98
32 (50.8) 42 (70) 0.03
21 (33.3) 12 (20) 0.10
17 (11.1) [27.0] 15 (8.3) [25] 0.60
4 (6.4) 6 (10) 0.46
13 (20.6) 19 (32.2) [31.7] 0.15
46 (73.0) 43 (71.7) 0.87
58 (92.1) 41 (68.3) 0.001
49 (3–264) 23 (5–151) <0.001
55 (87.3) 18 (30) <0.001
35 (55.6) 2 (3.3) <0.001
17 (27.0) 5 (8.3) 0.007
53 (84.1) 28 (47.5) [46.7] <0.001
52 (82.5) 21 (35.6) [35] <0.001
49 (77.8) 12 (20.3) [20] <0.001
16 (25.4) 6 (10.2) [10] 0.03
19 (30.2) 7 (11.9) [11.6] 0.01
36 (1–218) 19 (1–151) 0.005
29 (46.0) 17 (28.3) 0.04
ii from clinical specimens.
mia in the same hospital stay.
W.-H. Sheng et al. / International Journal of Infectious Diseases 14 (2010) e764–e769e768organisms include not only prior exposure to antibiotics, but also
variables related to host defense and infection control measures.
Previous reports have shown the risk factors for the acquisition of
CRAB to include disease severity (APACHE II score),20–23 prior
antibiotic use,10–13,21–29 invasive procedures such as catheteriza-
tions23,24,29 and mechanical ventilation,26 ICU stay,13,25–27 length
of hospital stay prior to CRAB acquisition,12,19,25 prior colonization
with A. baumannii,6,9 and a high work load.8 Compatible with these
reports, our study revealed that patients who carried A. baumannii
tended to be older, have chronic underlying diseases, and to have
previously received antimicrobial treatment. Our results also
showed that prolonged hospital stay, prior exposure to carbape-
nems, and prior hospitalization in the ICU were independent risk
factors associated with the acquisition of CRAB. Although we did
not ﬁnd the invasive procedures to be an independent risk factor
for the acquisition of CRAB, this might be due to the fact that
almost all patients had undergone invasive procedures during their
prolonged hospitalization and ICU stay; in addition, many of them
had had more than one invasive device in place simultaneously
when CRAB was isolated. These factors could interfere mutually
and attenuate their effects to each other.
In this study, we found that the risk factors for patients with
CRAB bacteremia were similar to those for patients with CRAB
infection or colonization. In addition, prior carriage of A. baumannii
was found to be a strong risk factor for the development of CRAB
bacteremia in the present study. Acinetobacter could contaminate
the environment and artiﬁcial devices easily, and survive in the
environment for a long time. Patients may become infected
following initial colonization, which may occur through cross-
transmission from healthcare workers or medical devices after a
prolonged hospital stay.30 Bacteremia may develop following
disruption of the skin and mucosa barrier of the patients through
insertion of medical devices, providing a portal of entry for A.
baumannii. These ﬁndings should alert clinicians to have a
heightened awareness and adherence to infection control mea-
sures in order to prevent the spread of CRAB in the hospital.
The inﬂuence of carbapenem resistance on the mortality of
patients infected with A. baumannii is still subject to debate. Some
studies have revealed no difference in mortality between patients
infectedwith CRAB and patients with CSAB.10,26,31 In this study, we
found that carbapenem resistance was one of the independent risk
factors for mortality in patients with A. baumannii bacteremia,
which is consistentwith the ﬁndings of other investigators.9,32,33 In
our previous study, we demonstrated that, due to a lack of effective
antibiotics, patients with infections due to extensively-drug-
resistant A. baumannii (including CRAB) had a very high mortality
rate.34 Underlying disease severity and the requirement for critical
care were two other factors that may explain the high mortality of
these patients infected with CRAB.
Our patients with the acquisition of CRAB and CRAB bacteremia
had a signiﬁcantly longer hospital stay after isolation of A.
baumannii than patients with CSAB. As prolonged hospitalization
is an important contributor to the excessive costs associated with
nosocomial complications, efforts to reduce the nosocomial
transmission of CRAB should be encouraged. In addition to the
decreased mortality and the economic beneﬁts that would result
from reducing CRAB infections, such efforts may also provide
beneﬁts in reducing the risk of transmission of other multi-
resistant organisms and the use of broad-spectrum antibiotics.
Previous reports have revealed that prior antibiotic
exposure, including exposure to ﬂuroquinolones,11,28 aminogly-
cosides,11,12,22 third-generation cephalosporins,13,21 and carba-
penems6,10,11,13,27,29 is a risk factor for the acquisition of CRAB.
Similar to those reports, our present study revealed that infection
or colonizationwith CRABwas related to the selection pressure of
broad-spectrum antibiotic use. The development of carbapenemresistance in A. baumannii in an environmentwhere carbapenems
are extensively used may confer a selective advantage for
nosocomial outbreaks, which further limits treatment options.
Also, the isolates of CRAB are often multidrug-resistant to
aminoglycosides, ﬂuoroquinolones, and broad-spectrum b-lac-
tams.35,36 Furthermore, most patients with CRAB infections are
critically ill and receive invasive life support measures, such as
endotracheal intubation with mechanical ventilator support,
central venous catheterization, and urinary catheterization. A
study revealed that the poor prognosis of patients with
Acinetobacter bacteremia was mainly due to a higher rate of
inappropriate treatment in cases of infection due to CRAB.33
Therefore, how to choose appropriate and effective antibiotic
regimens for treating patients with CRAB infections has become
an important and challenging issue for clinicians.
There were limitations in this study. First, this was a
retrospective study conducted at different medical centers and
regional hospitals, and the heterogeneity of the predisposing
factors and disease severity of the patients, choice of antibiotics
made for infections among the treating physicians, and complete-
ness of chart records might have precluded us from identifying all
the relevant factors that predisposed the patients to the acquisition
of A. baumannii. Second, half (n = 120) of the multicenter isolates
were collected from a single hospital (NTUH); however, the
distribution of CRAB and CSAB isolates, invasive procedures
performed, and types of patient care provided were similar in
these hospitals during the study period.
In conclusion, the acquisition of CRAB increases mortality and
length of hospital stay. Longer hospital stay, colonization with A.
baumannii, and admission to the ICU were associated with the
development of CRAB bacteremia.
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